市場調查報告書

全球硫酸軟骨素市場:成長,趨勢,及預測(2020年∼2025年)

Chondroitin Sulfate Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921900
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球硫酸軟骨素市場:成長,趨勢,及預測(2020年∼2025年) Chondroitin Sulfate Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

骨關節炎的高盛行率,是全球硫酸軟骨素市場主要成長要素。硫酸軟骨素不僅是在骨關節炎的治療,在眼科用藥的乾眼症治療,關節痛,高膽固醇,逆流性食道炎,間質性膀胱炎等,各種用途使用,用途的增加推動該市場整體成長。

本報告提供全球硫酸軟骨素市場的相關調查,市場機會和趨勢,成長及阻礙因素,各原料、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 骨關節炎的盛行率的增加
    • 硫酸軟骨素的成長用途
  • 市場阻礙因素
    • 硫酸軟骨素的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各原料
    • 鯊魚
    • 合成
    • 其他
  • 各用途
    • 醫藥品
    • 化妝品
    • 獸醫用
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bioiberica SAU
    • FIDIA FARMACEUTICI SPA,
    • GNOSIS SpA
    • Imprimis Pharmaceuticals, Inc.
    • 參天製藥株式會社
    • Merck KGaA (Sigma-Aldrich, Inc)
    • Synutra, Inc.
    • Summit Nutritionals International

第7章 市場機會及今後趨勢

目錄
Product Code: 67410

Market Overview

A high prevalence of osteoarthritis is the major driving factor for the growth of the Chondroitin Sulfate market. The National Institute of Health (NIH) stated in its report that over 30 million adults in the United States were diagnosed with osteoarthritis (OA) in the year 2017. The aging of the population and increasing obesity seen in all age groups are the prime causes of osteoarthritis in the country. Furthermore, increasing applications of chondroitin sulfate in various treatments is boosting the overall market growth for Chondroitin Sulfate globally. Not only in the treatment of osteoarthritis, but Chondroitin sulfate is also used in eye drops to treat dry eyes. Furthermore, it is also used in the solution to preserve cornea while transplantation during the cataract surgery. In April 2015, Santen Pharmaceutical Co., Ltd. launched New Sante de U α, an OTC eye drop with Chondroitin sulfate sodium as an active ingredient for relieving eye fatigue and preventing eye disease.

Scope of the Report

As per the scope of the report, Chondroitin sulfate is a glycosaminoglycan which is a major component of the extracellular matrix (ECM) of many connective tissues, including cartilage, bone, skin, ligaments, and tendons. In supplements, chondroitin sulfate usually comes from animal cartilage.

Key Market Trends

Pharmaceuticals segment holds significant market share

  • Chondroitin sulfate is majorly used for the treatment of osteoarthritis. It is often used in combination with other ingredients such as glucosamine sulfate, manganese ascorbate, N-acetyl glucosamine or glucosamine hydrochloride.
  • Chondroitin sulfate is also taken orally for heart attack, HIV/AIDS, heart disease, osteoporosis, joint pains because of the drugs used in the treatment of breast cancer, high cholesterol, muscle soreness after exercise, acid reflux, interstitial cystitis, Kashin-Beck disease, and psoriasis.
  • Chondroitin sulfate is approved by the FDA as an eye drops to treat dry eyes and also used as a solution to preserve cornea during cataract surgery. In 2017, Imprimis Pharmaceuticals Inc., an ophthalmology-focused pharmaceutical company, announced that it has entered into a licensing agreement for the exclusive worldwide rights to Klarity, ophthalmic topical solution, and gel technology for patients with a dry eye disease (DED)
  • Chondroitin sulfate is also used in combination with iron for the treatment of iron-deficiency anemia.
  • Chondroitin sulfate ointments in combination with glucosamine sulfate, shark cartilage, and camphor can be used for pain of osteoarthritis.
  • Some patients will inject chondroitin sulfate into muscles for osteoarthritis and some will insert chondroitin sulfate into the bladder for urinary tract infections, bladder conditions, or loss of bladder control.
  • As there is a wide range of medicinal applications of Chondroitin sulfate, the respective segment is expected to grow significantly.

North America holds the largest market share in Global Chondroitin Sulfate Market

The well-established pharmaceutical industry in the North America region and increasing USFDA approvals for chondroitin sulfate can be credited to the growth of the Chondroitin Sulfate Market in the region. High prevalence of osteoarthritis and increased use of cholesterol in cataract surgery and formulations for a drop in the eye are also a few factors that are enhancing the growth in North America. In November 2017, Gnosis launched the first dietary supplements with Mythocondro, the unique 100% vegan chondroitin sulfate similar to human synovial fluid into the USA market.

The Asia Pacific is estimated to be the fastest-growing region during the forecast period owing to the high incidence of osteoarthritis and growing awareness about the chondroitin sulfate applications in personal care and nutritional supplements.

Competitive Landscape

The market is moderately competitive due to the presence of many manufacturers. Competition in the market is moderate due to the increasing investments in R&D for product innovation and the increasing efficiency of the product by launching new products into the market. For instance, in April 2019 Fidia, launched CartiJoint FORTE, its first product in the dietary supplement category in the USA. CartiJoint FORTE also contains glucosamine hydrochloride and chondroitin sulfate. With the rising prevalence of osteoarthritis and other indications where Chondroitin Sulfate is used, it is believed that few small to mid-sized companies will penetrate the market in the future.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Osteoarthritis
    • 4.2.2 Growing Applications of Chondroitin Sulfate
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects of Chondroitin Sulfate
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Source
    • 5.1.1 Swine
    • 5.1.2 Shark
    • 5.1.3 Bovine
    • 5.1.4 Synthetic
    • 5.1.5 Others
  • 5.2 By Application
    • 5.2.1 Pharmaceuticals
    • 5.2.2 Cosmetics
    • 5.2.3 Veterinary Use
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bioiberica S.A.U
    • 6.1.2 FIDIA FARMACEUTICI S.P.A.,
    • 6.1.3 GNOSIS S.p.A.
    • 6.1.4 Imprimis Pharmaceuticals, Inc.
    • 6.1.5 Santen Pharmaceutical Co., Ltd.
    • 6.1.6 Merck KGaA (Sigma-Aldrich, Inc)
    • 6.1.7 Synutra, Inc.
    • 6.1.8 Summit Nutritionals International

7 MARKET OPPORTUNITIES AND FUTURE TRENDS